Ending our Spring 2024 CTML Seminar Series strong on April 17, we have speaker Dr. Bochra Zareini coming to speak. Her talk, "Does the Use of New Weight Loss Drugs/Diabetes Drugs (Glucagon-Like Peptide 1 Receptor Agonists) Increase the Risk of Depression, Suicide, and Self-Harm?" will take place at 12 PM at Berkeley Way West, 5th Floor, Room 5401.
Please note the talk date will be Wednesday, April 17.
The recent surge in the use of new weight loss and diabetes medications, specifically glucagon-like peptide 1 receptor agonists (GLP-1 RA), can be attributed to their dual benefits of significant weight loss and cardiovascular protection. However, since late 2023, concerning incidents of self-harm, suicide attempts, and suicidal ideation linked to these drugs have been reported in Iceland, prompting the European Medical Agency to monitor them closely. Post-authorization safety studies are crucial for confirming a drug's safety after it hits the market. Denmark's comprehensive national registries offer an excellent opportunity for extensive safety research, yet the application of targeted maximum likelihood estimation in such studies remains underutilized. In my presentation, I will provide an overview of the data sources, outline the methodological approach, and share preliminary findings on the association between GLP-1 RA and the risk of self-harm, suicide, and depression.
Where: Berkeley Way West | 5th Floor, Room 5401
When: Wednesday, April 17 | 12:00 PM